ALERT: This system is being upgraded on Tuesday December 12. It will not be available for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace will be disabled on Monday December 11, so no new items are to be added to the repository while the upgrade is in progress. Everything should be back to normal by the end of day, December 12.

Show simple item record

Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Hitzler, Johann K He, Wensheng Doyle, John Cairo, Mitchell Camitta, Bruce M Chan, Ka Wah Diaz Perez, Miguel A Fraser, Christopher Gross, Thomas G Horan, John T Kennedy-Nasser, Alana A Kitko, Carrie Kurtzberg, Joanne Lehmann, Leslie O'Brien, Tracey Pulsipher, Michael A Smith, Franklin O Zhang, Mei-Jie Eapen, Mary Carpenter, Paul A CIBMTR Pediatric Cancer Working Committee 2022-03-23T19:29:52Z 2022-03-23T19:29:52Z 2014-06
dc.identifier.issn 1545-5009
dc.identifier.issn 1545-5017
dc.description.abstract We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received myeloablative conditioning and 52% underwent transplantation in second remission. Disease-free survival (DFS) was 24% at a median of 3 years. Post-transplant leukemic relapse was more frequent than expected for children with DS-ALL (54%) than for non-DS ALL. These data suggest leukemic relapse rather than transplant toxicity is the most important cause of treatment failure. Advancements in leukemia control are especially needed for improvement in HCT outcomes for DS-ALL.
dc.language eng
dc.publisher Wiley
dc.relation.ispartof Pediatric blood & cancer
dc.relation.isversionof 10.1002/pbc.24918
dc.subject CIBMTR Pediatric Cancer Working Committee
dc.subject Humans
dc.subject Down Syndrome
dc.subject Graft vs Host Disease
dc.subject Genetic Predisposition to Disease
dc.subject Recurrence
dc.subject Tacrolimus
dc.subject Cyclosporine
dc.subject Antineoplastic Combined Chemotherapy Protocols
dc.subject Immunosuppressive Agents
dc.subject Myeloablative Agonists
dc.subject Disease-Free Survival
dc.subject Treatment Outcome
dc.subject Transplantation Conditioning
dc.subject Combined Modality Therapy
dc.subject Salvage Therapy
dc.subject Whole-Body Irradiation
dc.subject Remission Induction
dc.subject Bone Marrow Transplantation
dc.subject Hematopoietic Stem Cell Transplantation
dc.subject Registries
dc.subject Retrospective Studies
dc.subject Adolescent
dc.subject Adult
dc.subject Child
dc.subject Child, Preschool
dc.subject Infant
dc.subject Living Donors
dc.subject Precursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject Kaplan-Meier Estimate
dc.subject Allografts
dc.title Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.
dc.type Journal article Kurtzberg, Joanne|0097203 2022-03-23T19:29:52Z
pubs.begin-page 1126
pubs.end-page 1128
pubs.issue 6
pubs.organisational-group Duke
pubs.organisational-group School of Medicine
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Institutes and Centers
pubs.organisational-group Pathology
pubs.organisational-group Pediatrics
pubs.organisational-group Duke Cancer Institute
pubs.organisational-group Institutes and Provost's Academic Units
pubs.organisational-group Initiatives
pubs.organisational-group Duke Innovation & Entrepreneurship
pubs.organisational-group Pediatrics, Transplant and Cellular Therapy
pubs.publication-status Published
pubs.volume 61
duke.contributor.orcid Kurtzberg, Joanne|0000-0002-3370-0703

Files in this item


This item appears in the following Collection(s)

Show simple item record